| Proteolysis-targeting chimera (PROTAC) delivery system: Advancing protein degraders towards clinical translation Y Chen, I Tandon, W Heelan, Y Wang, W Tang, Q Hu Chemical Society Reviews 51 (13), 5330-5350, 2022 | 127 | 2022 |
| Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries B Wang, J Liu, I Tandon, S Wu, P Teng, J Liao, W Tang European journal of medicinal chemistry 219, 113425, 2021 | 50 | 2021 |
| Development of substituted phenyl dihydrouracil as the novel achiral cereblon ligands for targeted protein degradation H Xie, C Li, H Tang, I Tandon, J Liao, BL Roberts, Y Zhao, W Tang Journal of Medicinal Chemistry 66 (4), 2904-2917, 2023 | 26 | 2023 |
| Synthesis of novel cereblon e3 ligase ligands, compounds formed thereby, and pharmaceutical compositions containing them W Tang, H Xie, Y Wu, J Liao, C Li, I Tandon, H Tang US Patent App. 18/426,920, 2024 | | 2024 |
| Development and Characterization of Third Generation MDM2 PROTACs for the Treatment of Acute Myeloid Leukemia Utilizing an Achiral Ligand for E3 Ligase Cereblon I Tandon, Q Fan, C Li, N Pannilawithana, H Xie, P Esguerra, W Tang Journal of Pharmacology and Experimental Therapeutics 385 (S3), 2023 | | 2023 |
| REVISITING THE NF-KAPPAB AXIS IN MLL-REARRANGED LEUKEMIA T Vu, W Liao, W Yang, I Tandon, P Ernst Experimental Hematology 76, S91, 2019 | | 2019 |
